In a phase 3 trial, upadacitinib, an oral Janus kinase inhibitor approved for rheumatoid arthritis, was more effective than placebo and noninferior to adalimumab among patients with psoriatic arthritis who’d had an inadequate response to nonbiologic disease-modifying antirheumatic drugs. Adalimumab is a subcutaneously injected tumor necrosis factor α inhibitor used to treat rheumatoid arthritis and psoriatic arthritis.
The trial’s 1704 patients at 281 sites in 45 countries were randomly assigned to receive 15 mg or 30 mg of oral upadacitinib once daily, placebo, or 40 mg of subcutaneous adalimumab every other week. The primary end point was at least 20% improvement in the number of tender and swollen joints and at least 20% improvement in 3 out of 5 other domains at week 12.
Slomski A. Upadacitinib Noninferior to Adalimumab for Psoriatic Arthritis. JAMA. 2021;325(20):2039. doi:10.1001/jama.2021.7716
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: